Oxford-based international medical imaging company Mirada Medical has appointed Dr Mark Crockett (pictured) as its new Chief Medical Officer (CMO). An experienced physician with a history of leadership in medical technology companies, Crockett joins the Mirada team to drive clinical validation, innovation and increase the company's leadership in oncology treatment guidance.
This is the first senior appointment made by new Mirada Medical CEO, Jon DeVries, who said: "Mark is a proven technology leader who will help us accelerate the delivery of our vision for improving cancer care for millions. We have an enormous task in the field of oncology – to increase survival rates by empowering clinicians to make diagnoses, plan personalised treatments, and more effectively perform radiation therapy through quantitative image analysis and disease characterisation."
Mirada Medical partners with firms such as Boston Scientific, Canon, Philips and GE Health, and develops AI-based applications that help healthcare professionals improve outcomes for cancer patients. The company’s products are used in leading hospitals around the globe, including Johns Hopkins, the Netherlands Cancer Institute and University Hospitals Oxford. Over five million patients per year are now treated by Mirada’s products worldwide.
Like CEO DeVries, Crockett is based out of Chicago. He joins the company during a period of significant expansion, following record growth in the last 12 months.
Duane Lawrence, Mirada Chairman, commented: "With Jon and Mark in the US, and the senior leaders already within the UK, we have established a fantastic global footprint. We already operate in thousands of clinics worldwide, and we will be able to help thousands more in delivering more effective treatment to cancer patients."
Based in Oxford with an international presence, Mirada Medical employs over 70 staff. The company develops advanced technology AI-based applications that help healthcare professionals use medical images more effectively and efficiently to improve cancer care. Mirada’s products are used across diagnostic radiology, molecular imaging, radiation oncology, medical oncology, tumour board and elsewhere.